Cibinqo (abrocitinib) / Pfizer, Glenmark - LARVOL DELTA

New-onset psoriasis with abrocitinib therapy for atopic dermatitis. (PubMed, JAAD Case Rep) - No abstract available

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

The Efficacy of Off-Label Abrocitinib in Alopecia Areata: A Systematic Review (CDA 2025) - "Among the six patients with comorbid AD, clinical improvement of AD was reported in 4 patients without additional therapy, while one patient experienced improvement with concurrent dupilumab treatment (one unreported). Conclusions The current data for abrocitinib use in alopecia is promising. Research with large-scale, randomized controlled trials will be needed to determine optimal dosing and quantify clinical benefit from abrocitinib therapy ."

Clinical • Review • Alopecia • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Respiratory Diseases

JAK-1 Inhibitors in the Management of Atopic Dermatitis in Older Adults: A Descriptive Cohort Study (CDA 2025) - "Janus kinase inhibitors (JAK-1 inhibitors), such as upadacitinib and abrocitinib, have emerged as effective treatments for moderate-to-severe AD. A retrospective cross-sectional study that examined patients aged 65 years or older treated at Pitanga Clinic in Hamilton, Ontario with a documented diagnosis of AD. Data were extracted from electronic medical records and included demographics, disease characteristics, and treatment specifics. Disease control was assessed using the Atopic Dermatitis Control Tool (ADCT), while adverse events were analyzed."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Treatment of Refractory PRP with Off-label Guselkumab and Abrocitinib: A Promising Combination Therapy (CDA 2025) - "She had failed NBUVB phototherapy, cyclosporine, topical steroids and keratolytics, prednisone, and was currently taking acitretin alternating dose 25mg/35mg daily...She started combination of methotrexate and acitretin which failed. Ustekinumab 90mg every twelve weeks was initiated off-label with alitretinoin 30mg daily; no change...Current treatments approved for both psoriasis and atopic dermatitis seem to provide benefit, and combination therapy may be more beneficial. More research is necessary to find an effective single agent or to identify ideal doses of combination therapies."

Combination therapy • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Immunology • Pruritus • Psoriasis • IL23A

Both Upadacitinib and Abrocitinib Demonstrate Real-World Efficacy in AD Patients After 1 Year (DermatologyTimes) - "Positive retrospective study data has confirmed upadacitinib and abrocitinib's efficacy for moderate-to-severe atopic dermatitis (AD) in real-world settings....Positive results were seen in both cohorts as early as 8 weeks into the trial. These rates continued to rise through 16 and 32 weeks. However, patients treated with abrocitinib at the same time point were less likely to achieve complete skin clearance (EASI 100) compared to those treated with upadacitinib (p = 0.017). After 1 year of treatment with upadacitinib, 88.9% reached EASI75, 70.8% reached EASI90, and 54.2% reached complete skin clearance of EASI100. After 1 year of treatment with abrocitinib, 100% reached EASI75, 91.7% reached EASI90, and 75% reached EASI100. After 52 weeks, 100% of patients taking abrocitinib reached IGA 0/1 compared to 84.7% of patients taking upadacitinib."

Retrospective data • Atopic Dermatitis

Wells syndrome: emerging triggers and treatments- an updated systematic review. (PubMed, Arch Dermatol Res) - "Recent literature expands the clinical spectrum of Wells syndrome, highlighting new immunologic and iatrogenic triggers. Targeted treatments, especially biologics and Janus kinase inhibitors, demonstrate promising results and may offer steroid-sparing alternatives for patients with refractory disease. Clinicians should consider emerging triggers in differential diagnosis and evaluate newer therapies in recurrent or treatment-resistant cases. Further prospective and registry-based studies are warranted to validate efficacy and support development of evidence-based management guidelines."

Journal • Review • Dermatology • Infectious Disease • Influenza • Novel Coronavirus Disease • Oncology • Pediatrics • Respiratory Diseases

Comparing JAK Inhibitors and Standard Therapies in Refractory Myopathies: Impact on Cardiovascular, Malignancy, and Disease Activity Outcomes (EULAR 2025) - "The cohorts were defined by treatment exposure: patients receiving JAK inhibitors (tofacitinib, ruxolitinib, abrocitinib, upadacitinib, filgotinib, or baricitinib) were compared to those receiving standard therapies (methotrexate, azathioprine, IVIG, rituximab, or mycophenolate mofetil). JAK inhibitors demonstrated significant benefits in reducing MACE, stroke, CAD, heart failure, thrombosis, vascular disease, malignancy, and CK-based disease activity in patients with DM, ASS, and IMNM compared to standard therapies. However, these advantages, the higher all-cause mortality observed in the JAK inhibitor cohort underscores the importance of careful risk stratification and close monitoring. These findings highlight the therapeutic potential of JAK inhibitors in refractory myopathies, warranting further investigation in randomized controlled trials to validate these results and refine treatment strategies for inflammatory myopathies."

Atherosclerosis • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Dermatomyositis • Diabetes • Heart Failure • Metabolic Disorders • Myositis • Oncology • Rare Diseases • Solid Tumor • Thrombosis

Characterizing Atopic Dermatitis and Abrocitinib Early Response Through Tape-Stripped and Serum Biomarkers. (PubMed, Dermatitis) - " Extrinsic AD shares Th2-type inflammation with intrinsic AD, but intrinsic AD shows elevated Th17/Th22-type inflammation. Biomarker integration models can contribute to precise AD treatment."

Biomarker • Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation • CCL22

Late-Breaking Data: Flexible Dosing of Abrocitinib for AD Shows Real-World Promise (DermatologyTimes) - P=NA | N=NA | JADE REAL (NCT04564755) | "The Revolutionizing Atopic Dermatitis (RAD) 2025 meeting in Nashville, Tennessee, showcased a wide range of innovations in the management of atopic dermatitis (AD)....JADE REAL (NCT04564755) was initiated in 2020 and completed in September 2024.2 It enrolled 312 patients aged ≥12 years with moderate to severe AD who lacked adequate treatment options....Treatment-emergent adverse events (TEAEs) led to dose reductions in 8.7% (n=27) of participants and dose escalations in 3.8% (n=12). The most commonly reported TEAEs prompting dose reduction included nausea, thrombocytopenia, acne, fatigue, and folliculitis-each affecting about 1% of the cohort. Notably, atopic dermatitis itself was the only adverse event leading to dose escalation in more than 1% of patients."

Clinical data • Late-breaking abstract • Real-world • Atopic Dermatitis

A Case of Intense Pulsed Light Aggravated Rosacea Successfully Treated by Abrocitinib. (PubMed, Clin Cosmet Investig Dermatol) - "Subsequent treatment with oral abrocitinib for 12 weeks led to a gradual resolution of the patient's facial symptoms. Therefore, we hypothesized that the oral JAK-1 inhibitor abrocitinib not only serves as a promising new treatment option for rosacea but also offers therapeutic benefits in cases of inappropriate phototherapy."

Journal • Dermatology • Pain • Rosacea

Clinical Assessment of Abrocitinib, Tofacitinib, and Cyclosporine in Adult Patients With Moderate to Severe Atopic Dermatitis: A Retrospective Analysis. (PubMed, Cureus) - "In our small sample-sized analysis, all treatment groups were found to be efficacious and safe. However, abrocitinib showed a better clinical response than the other two groups in achieving symptom control. However, due to the small sample size, these claims can't be generalized, and further large-scale studies are needed to validate these findings and assess long-term outcomes."

Journal • Retrospective data • Atopic Dermatitis • Cardiovascular • Dermatitis • Dermatology • Hypertension • Immunology • Infectious Disease • Inflammation • Pain • Pruritus

Successful Treatment of Necrobiosis Lipoidica with Abrocitinib: A Case Report. (PubMed, Case Rep Dermatol) - "Abrocitinib may represent a rapid and safe treatment option for patients with refractory localized NL. Further studies are warranted to confirm these findings and evaluate long-term efficacy."

Journal • Metabolic Disorders

Novel use of abrocitinib in refractory ulcerative panniculitis with vasculitis: a case report. (PubMed, Clin Exp Rheumatol) - No abstract available

Journal • Vasculitis

SAT 04 Ask the Experts: Optimizing Atopic Dermatitis Treatment With Abrocitinib (EADV-Sp 2025) - "This session is sponsored by: Pfizer"

Atopic Dermatitis • Dermatitis • Dermatology • Immunology

“Based on the review of the data on safety and efficacy, the benefit-risk balance of Cibinqo (abrocitinib) in the approved indication(s) remains unchanged” (European Medicines Agency) - Pharmacovigilance Risk Assessment Committee (PRAC) Minutes of meeting on 7 – 10 Apr 2025: “Nevertheless, the product information should be updated to include neutropenia as an undesirable effect with a frequency ‘uncommon’. Therefore, the current terms of the marketing authorization should be varied”

PRAC • Atopic Dermatitis • Dermatitis • Immunology • Inflammation

Association of sebaceous carcinoma and Janus kinase inhibitors: Case study and retrospective FAERS analysis (SID 2025) - "Ruxolitinib, first approved in 2011, has been in use longer than abrocitinib (approved in 2022) or upadacitinib (approved in 2019), which could explain the minimal reports for other JAKi-associated SC. No signal was detected for tofacitinib in our study. While tofacitinib (approved in 2012) and ruxolitinib have been on the market for similar periods of time, ruxolitinib may pose a greater risk for skin cancer than tofacitinib."

Case study • Late-breaking abstract • Retrospective data • Genetic Disorders • Immunology • Oncology • Skin Cancer

Nuevas fronteras en el tratamiento de la dermatitis de contacto alérgica: el rol de las terapias emergentes. (PubMed, Actas Dermosifiliogr) - "This article aims to review the current available data on the use of biologic drugs and small molecule inhibitor drugs in the management of ACD. Results suggest that iJAKs, such as abrocitinib, tofacitinib, upadacitinib, and baricitinib; although biologic drugs, such as dupilumab show significant promise in refractory ACD, more long-term clinical trials are needed to confirm their safety and efficacy profile."

Journal • Review • Contact Dermatitis • Dermatitis • Dermatology • Immunology

Radiation Exposure Induced Blood-Brain Barrier Injury via Mitochondria-Mediated Sterile Inflammation. (PubMed, Adv Sci (Weinh)) - "Furthermore, it is found abrocitinib (JAK1 inhibitor) and idebenone (mitochondrial protectant) can attenuate radiation-induced inflammation and ameliorate injuries in the BBB MPS. These findings reveal the involvement of mitochondria-mediated sterile inflammation in RIBI pathogenesis, identifying mitochondria as a potential target for new radioprotective measures."

Journal • CNS Disorders • Cognitive Disorders • Inflammation • Vascular Neurology

Real-world evaluation of efficacy and safety of abrocitinib in moderate-to-severe atopic dermatitis across a multi-site hospital system (SID 2025) - "96% of patients had prior exposure to systemic therapy, which they had discontinued due to inadequate response or intolerance before initiating abrocitinib, including prior treatment with dupilumab (80%), prednisone (34%), and upadacitinib (10%). No serious adverse events occurred. Abrocitinib was well-tolerated and effective across various age, sex, race, or ethnicity and demonstrated strong therapeutic potential in refractory cases where other systemic therapies failed."

Clinical • HEOR • Late-breaking abstract • Real-world • Real-world evidence • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Pain

Effects of JAK/STAT inhibitors in cutaneous T-cell lymphoma cells (SID 2025) - "Four JAK inhibitors were tested: Abrocitinib (JAK1), Tofacitinib (pan-JAK, potent JAK3 inhibition), Ritlecitinib (JAK3), and Brepocitinib (pan-JAK, potent TYK2/JAK1 inhibition). Notably, Tofacitinib combined with AS1517499 or TTI-101 showed synergistic apoptotic effects, as did the combination of the two STAT inhibitors. These findings underscore the efficacy of JAK/ STAT inhibitors in MJ and HuT 78 cells, highlight differential sensitivities between the cell lines, and support ongoing investigations into the underlying mechanisms."

Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma • JAK1 • JAK3 • STAT3 • STAT6 • TYK2

Clinical efficacy and endotype changes in Chinese atopic dermatitis patients after abrocitinib treatment (SID 2025) - "Compared to dupilumab, abrocitinib showed greater improvement in Itch-NRS at week 2 and a higher proportion of EASI-75 at week 4. WGCNA identified an efficacy-related gene module, leading to a five-gene (PLN2, CAT, CLC, RAB44, SMPD3) efficacy-predictive model. In conclusion, Abrocitinib demonstrated robust efficacy and a well-tolerated safety profile in Chinese patients with moderate-to-severe AD in routine clinical practice, accompanied by normalization of elevated blood biomarkers and dysregulated blood transcripts."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Infectious Disease • Respiratory Diseases • Tuberculosis • CCL18 • IL10 • IL2RA • IL5 • IL6 • ISG20 • TNFA

52-week long-term follow-up of non-segmental vitiligo treated with oral abrocitinib and narrow-band UVB phototherapy (SID 2025) - "Repigmentation on the face, trunk, and even distal extremities may be improved when oral abrocitinib treatment course is prolonged. Nevertheless, patients who developed treatment resistance (with no repigmentation on any part of the body) after 24 weeks would not benefit from an extension of the treatment duration."

Dermatology • Immunology • Vitiligo • CCL20 • IFNG

Abrocitinib reduces circulating, skin homing, and resident memory T-cells in atopic dermatitis samples in vitro and ex vivo, and disease flare severity in a humanized mouse model (SID 2025) - "This was revealed by transcriptomic and histological analysis, as well as the detection of higher filaggrin and claudin-1 expression, and lower CD3+ cells in treated versus control xenotransplants. Taking together, our data indicate that Abrocitinib impacts breakthrough AD flare severity potential and possess interesting disease modifying properties linked, at least in part, also to its ability to interfere with the expansion/survival of TM."

IO biomarker • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • CCR4 • CD69 • CD8 • CLDN1 • FLG

Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis). (PubMed, Arch Dermatol Res) - "Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib) may offer a valuable alternative. No statistically significant differences in terms of efficacy and safety were found among the treatment groups. JAK inhibitors demonstrated significant efficacy and an acceptable safety profile in elderly AD patients."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus

Successful Treatment of Cutaneous Foreign Body Granuloma with JAK Inhibitor Abrocitinib and Prednisone: A Case Report. (PubMed, Clin Cosmet Investig Dermatol) - "This report provides preliminary evidence for JAK inhibitors' efficacy in managing refractory filler-induced FBG. Large-scale controlled trials are warranted to validate long-term safety and therapeutic benefits."

Journal • Aesthetic Medicine • Inflammation